Acute lung injury (ALI) is characterized by overwhelming
lung inflammation and anti-
inflammation treatment is proposed to be a therapeutic strategy for ALI.
Agmatine, a cationic
polyamine formed by decarboxylation of
L-arginine, is an endogenous
neuromodulator that plays protective roles in diverse central nervous system (CNS) disorders. Consistent with its neuromodulatory and neuroprotective properties,
agmatine has been reported to have beneficial effects on depression, anxiety, hypoxic
ischemia,
Parkinson's disease, and gastric disorder. In this study, we tested the effect of
agmatine on the
lung inflammation induced by
Zymosan (ZYM) challenge in mice. We found that
agmatine treatment relieved ZYM-induced
acute lung injury, as evidenced by the reduced histological scores, wet/dry weight ratio, and
myeloperoxidase activity in the lung tissue. This was accompanied by reduced levels of TNF-α, IL-1β, and
IL-6 in lung and bronchoalveolar lavage fluid and decreased iNOS expression in lung. Furthermore,
agmatine inhibited the phosphorylation and degradation of IκB and subsequently blocked the activation of nuclear factor (NF)-κB induced by
Zymosan. Taken together, our results showed that
agmatine treatment inhibited NF-κB signaling in lungs and protected mice against ALI induced by
Zymosan, suggesting
agmatine may be a potential safe and effective approach for the treatment of ALI.